The US Food and Drug Administration (FDA) has approved methylphenidate hydrochloride (Adhansia XR) for the treatment of ADHD in patients aged 6 years and older. The central nervous system (CNS) stimulant from Adlon Therapeutics—a Purdue Pharma subsidiary—was approved as an extended-released capsule intended to serve as a first-line ADHD therapy.